Literature DB >> 25337284

Chronic bronchitis with fungal infection presenting with marked elevation of serum carbohydrate antigen 19-9: a case report.

Ping Han1, Wei Yan1, Yi Luo2, Wei Tu1, Jia-Yi He1, Jing-Mei Liu1, Jin Gong1, Yun-Wu Wang1, Meng-Ke Li1, De-An Tian1, Huan-Jun Huang1.   

Abstract

Carbohydrate antigen 19-9 (CA19-9) is the most frequently applied serum tumor marker for diagnosis of cancers in the digestive organs. However, some patients with benign diseases can have elevated serum levels of CA19-9 as well. The current study presents a 55-year-old female who was admitted to our hospital for further evaluation of a nodular cavity shadow in the right lower lobe and clarification of the cause of the marked elevation of serum CA19-9 levels. Abdominal MRI and gastrointestinal endoscopy did not find any malignancy. As lung cancer cannot be excluded in this patient, a video-assisted thoracoscopic surgery was carried, intraoperative and postoperative biopsy analysis both suggested chronic bronchitis with fungal infection (due to Histoplasma capsulatum or Penicillium marneffei) and organization. Immunohistochemistry showed marked positive staining for CA19-9 in the damaged lung tissue. The CA19-9 levels quickly returned to the normal range following lobe resection. Therefore, the marked elevation of serum CA19-9 levels, in this case, may have resulted from the chronic bronchitis with fungal infection.

Entities:  

Keywords:  Carbohydrate antigen 19-9; chronic bronchitis; fungal infection; immunohistochemistry

Mesh:

Substances:

Year:  2014        PMID: 25337284      PMCID: PMC4203255     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  [Increased CA19-9 level in serum and bronchoalveolar lavage fluid from a patient with pulmonary tuberculosis].

Authors:  Y Ishiura; M Fujimura; S Minami; A Ueda; M Iwata; K Watanabe; T Shinagawa; M Yasui; T Matsuda; M Kitagawa
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1996-04

2.  Small-cell lung cancer and elevated CA 19.9 tumor marker levels.

Authors:  José María Prieto De Paula; Eduardo Mayor Toranzo; Laura Gallardo Borge; Silvia Franco Hidalgo
Journal:  Arch Bronconeumol       Date:  2012-05-02       Impact factor: 4.872

3.  [Silicosis characterized by increasing serum CA 19-9 in parallel with progression of lung fibrosis].

Authors:  Y Totani; Y Demura; S Ameshima; T Ishizaki; I Miyamori
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2000-02

4.  Role of hepatic dysfunction and bilirubin on CA 19-9 levels in cirrhotic patients.

Authors:  G Leandro; S Zizzari; O G Manghisi
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

5.  Serum levels of CA19-9 in patients with nonmalignant respiratory diseases.

Authors:  Takahide Kodama; Hiroaki Satoh; Hiroichi Ishikawa; Morio Ohtsuka
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

6.  Modulation of immune responses in murine pulmonary histoplasmosis.

Authors:  R Allendoerfer; G P Biovin; G S Deepe
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  Increased CA 19-9 level in patients without malignant disease.

Authors:  Hye-Ryoun Kim; Chang-Hyun Lee; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

8.  Factors affecting serum levels of CA 19-9 with special reference to benign hepatobiliary and pancreatic diseases.

Authors:  N Sawabu; Y Takemori; D Toya; M Yoneshima; H Kidani; Y Satomura; H Ohta; N Hattori
Journal:  Gastroenterol Jpn       Date:  1986-10

9.  CA 19-9 and pancreatic adenocarcinoma.

Authors:  F Safi; H G Beger; R Bittner; M Büchler; W Krautzberger
Journal:  Cancer       Date:  1986-02-15       Impact factor: 6.860

10.  Pulmonary sequestration presenting with left upper abdominal bloating and marked elevation of serum carbohydrate antigen 19-9: A case report.

Authors:  Ping Han; Yi Luo; Dean Tian; Wei Yan; Jingmei Liu; Ying Chang; Huaping Xie; Wang Wei; Huanjun Huang
Journal:  Oncol Lett       Date:  2014-03-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.